T
Thomas M. Roston
Researcher at University of British Columbia
Publications - 63
Citations - 1062
Thomas M. Roston is an academic researcher from University of British Columbia. The author has contributed to research in topics: Catecholaminergic polymorphic ventricular tachycardia & Medicine. The author has an hindex of 13, co-authored 47 publications receiving 639 citations. Previous affiliations of Thomas M. Roston include University of Alberta.
Papers
More filters
Journal ArticleDOI
Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.
Thomas M. Roston,Jeffrey M. Vinocur,Kathleen R. Maginot,Saira Mohammed,Jack C. Salerno,Susan P. Etheridge,Mitchell B. Cohen,Robert M. Hamilton,Andreas Pflaumer,Ronald J. Kanter,James E. Potts,Martin J. LaPage,Kathryn K. Collins,Roman Gebauer,Joel Temple,Anjan S. Batra,Christopher C. Erickson,Maria Miszczak-Knecht,Peter Kubuš,Yaniv Bar-Cohen,Michal J. Kantoch,Vincent C. Thomas,Gabriele Hessling,Chris Anderson,Ming-Lon Young,Michel Cabrera Ortega,Yung R. Lau,Christopher L. Johnsrude,Anne Fournier,Prince J. Kannankeril,Shubhayan Sanatani +30 more
TL;DR: This study demonstrates a malignant phenotype and lengthy delay to diagnosis in catecholaminergic polymorphic ventricular tachycardia, and implantable cardioverter defibrillators were common despite numerous device-related complications.
Journal ArticleDOI
The role of the autonomic nervous system in arrhythmias and sudden cardiac death
Sonia Franciosi,Frances Perry,Thomas M. Roston,Kathryn Armstrong,Victoria E. Claydon,Shubhayan Sanatani +5 more
TL;DR: Increasing evidence suggests that modulation of the autonomic nervous system as a therapeutic strategy in the treatment of cardiac arrhythmias is safe and effective and further studies investigating the involvement of the ANS in arrhythmia pathogenesis and its modulation for the treatment for cardiac arrHythmias are warranted.
Journal ArticleDOI
Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest
Christian van der Werf,Krystien V.V. Lieve,J. Martijn Bos,Conor M. Lane,Isabelle Denjoy,Ferran Rosés-Noguer,Takeshi Aiba,Yuko Wada,Jodie Ingles,Jodie Ingles,Ida S. Leren,Boris Rudic,Peter J. Schwartz,Alice Maltret,Frederic Sacher,Jonathan R. Skinner,Jonathan R. Skinner,Andrew D. Krahn,Thomas M. Roston,Jacob Tfelt-Hansen,Heikki Swan,Tomas Robyns,Seiko Ohno,Jason D. Roberts,Maarten P. van den Berg,Janneke A.E. Kammeraad,Vincent Probst,Prince J. Kannankeril,Nico A. Blom,Nico A. Blom,Elijah R. Behr,Elijah R. Behr,Martin Borggrefe,Kristina H. Haugaa,Christopher Semsarian,Christopher Semsarian,Minoru Horie,Wataru Shimizu,Janice A. Till,Antoine Leenhardt,Michael J. Ackerman,Arthur A.M. Wilde,Arthur A.M. Wilde +42 more
TL;DR: In previously undiagnosed patients with CPVT who presented with SCA, an ICD was not associated with improved survival and was associated with both a high rate of appropriate I CD shocks and inappropriate ICD shocks along with other device-related complications.
Journal ArticleDOI
The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.
Thomas M. Roston,Zhiguang Yuchi,Prince J. Kannankeril,Julie Hathaway,Jeffrey M. Vinocur,Susan P. Etheridge,James E. Potts,Kathleen R. Maginot,Jack C. Salerno,Mitchell I. Cohen,Robert M. Hamilton,Andreas Pflaumer,Saira Mohammed,Lynn Kimlicka,Ronald J. Kanter,Martin J. LaPage,Kathryn K. Collins,Roman Gebauer,Joel Temple,Anjan S. Batra,Christopher C. Erickson,Maria Miszczak-Knecht,Peter Kubuš,Yaniv Bar-Cohen,Michal J. Kantoch,Vincent C. Thomas,Gabriele Hessling,Chris Anderson,Ming-Lon Young,Sally H.J. Choi,Michel Cabrera Ortega,Yung R. Lau,Christopher L. Johnsrude,Anne Fournier,Filip Van Petegem,Shubhayan Sanatani +35 more
TL;DR: This large, multicentre study identifies contemporary challenges related to the diagnosis and prognostication of CPVT patients andStructural modelling of RyR2 can improve the understanding of severe CPVT phenotypes.
Journal ArticleDOI
Cardiac ryanodine receptor calcium release deficiency syndrome
Bo Sun,Bo Sun,Jinjing Yao,Mingke Ni,Jinhong Wei,Xiaowei Zhong,Wenting Guo,Lin Zhang,Ruiwu Wang,Darrell D. Belke,Yong-Xiang Chen,Krystien V.V. Lieve,Anders Krogh Broendberg,Thomas M. Roston,Ivan Blankoff,Janneke A.E. Kammeraad,Johannes C. von Alvensleben,Julieta Lazarte,Alexander Vallmitjana,Loryn J. Bohne,Robert A. Rose,Raul Benitez,Leif Hove-Madsen,Carlo Napolitano,Robert A. Hegele,Michael Fill,Shubhayan Sanatani,Arthur A.M. Wilde,Jason D. Roberts,Silvia G. Priori,Henrik Jensen,S. R. Wayne Chen,S. R. Wayne Chen +32 more
TL;DR: In this article, the authors performed clinical and genetic evaluations of individuals who suffered from sudden cardiac death (SCD) and harbored an LOF RyR2 mutation, which can be reproduced on exercise stress testing (EST).